Tivantinib Improves Survival in HCC Patients

Share this content:

(ChemotherapyAdvisor) – Tivantinib increases time to tumor progression (TTP) and survival in patients with Met-positive hepatocellular carcinoma (HCC), according to the results of a phase 2 study presented at the 2012 Association for Clinical Oncology. The abstract was entitled “Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).”

Tivantinib (T) inhibits c-Met, the tyrosine kinase receptor involved in tumor cell migration, invasion, proliferation and angiogenesis in hepatocellular carcinoma (HCC). Tivantinib has shown promising results in HCC in phase 1 studies as monotherapy and in combination with sorafenib, noted lead author Lorenza Rimassa, MD, Deputy Director, Medical Oncology Unit, Humanitas Cancer Center, Milan, Italy. 

In this multi-center, randomized, controlled study, patients were randomized to oral tivantinib [360mg, twice a day (A), 240mg twice a day, (B) or placebo (P). The primary end point was TTP, secondary end points included disease control rate (DCR), PFS, OS, efficacy in Met-positive patients, and safety.

The investigators reported that major TTP, DCR and PFS benefits were obtained in Met+ pts, with preliminary OS positively trending in the tivantinib arm (HR=0.47) and no detrimental effect in Met- pts. The most common drug-related adverse events were neutropenia (25.4%) and anemia (15.5%).

The investigators concluded that, compared to placebo, tivantinib significantly benefited second-line HCC patients, especially if they were Met-positive, with a manageable safety profile at 240mg twice a day.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs